Patents by Inventor Jack Elias

Jack Elias has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS AND COMPOSITIONS RELATING TO BISPECIFIC ANTI-CHI3L1 ANTIBODY REAGENTS
    Publication number: 20240076407
    Abstract: It is demonstrated herein that inhibitors of immune checkpoints and CHI3L1 are synergistic. Accordingly, described herein are methods and compositions relating to combinatorial therapies for cancer, e.g., comprising an inhibitor of CHI3L1; and an inhibitor of an immune checkpoint protein. In some embodiments, the CHI3L1 inhibitor can be an antibody or antibody reagent as described herein.
    Type: Application
    Filed: April 20, 2023
    Publication date: March 7, 2024
    Inventors: Jack A. ELIAS, Chun Geun LEE, Chuan Hua HE, Bing MA, Suchitra Kamle, Chang-Min LEE
  • METHODS AND COMPOSITIONS RELATING TO ANTI-CHI3L1 ANTIBODY REAGENTS
    Publication number: 20230406958
    Abstract: Described herein are methods and compositions relating to anti-Chi3L1 antibodies, antibody reagents, and antigen-binding fragments thereof which display superior properties, e.g., high sensitivity, high specificity, high binding affinity, neutralization activity ex vivo and in vivo (e.g., blocks Chi3L1-induced MAPK and AKT signaling). Methods of treatment, e.g., of treating cancer, obesity, and/or asthma by administering the compounds described herein are also provided.
    Type: Application
    Filed: April 20, 2023
    Publication date: December 21, 2023
    Inventors: Jack A. Elias, Chun Geun Lee, Chuan Hua He, Bing Ma, Suchitra Kamle, Chang-Min Lee
  • METHODS FOR PREVENTING, REVERSING OR TREATING AN INFECTION INDUCED BY A VIRUS THAT ENTERS HOST CELLS VIA ACE2 RECEPTOR
    Publication number: 20230312752
    Abstract: Described herein are methods of preventing, reversing, and/or treating an infection induced by a virus that enters cells via the cellular receptor Angiotensin-Converting Enzyme 2 (ACE2) by administering an inhibitor of CHI3L1.
    Type: Application
    Filed: November 22, 2022
    Publication date: October 5, 2023
    Inventors: Jack A. ELIAS, Chun Geun LEE, Suchitra KAMLE, Bing MA, Changmin Lee
  • Methods and compositions relating to the treatment of fibrosis
    Patent number: 11717528
    Abstract: Described herein are methods of treating fibrosis and fibrotic diseases with certain aminoglycosides, e.g., kasugamycin derivatives thereof.
    Type: Grant
    Filed: January 7, 2022
    Date of Patent: August 8, 2023
    Assignee: BROWN UNIVERSITY
    Inventors: Jack A. Elias, Chun Geun Lee, Chang-Min Lee
  • METHODS FOR PREVENTING, REVERSING OR TREATING A COVID-19 INFECTION
    Publication number: 20230183323
    Abstract: Covid-19 is caused by a highly transmissible novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or a variant thereof. Current available therapeutic modalities have significant efficacy issues. Described herein are methods of preventing, reversing, and/or treating a Covid-19 infection by administering an inhibitor of CHI3L1.
    Type: Application
    Filed: May 19, 2021
    Publication date: June 15, 2023
    Inventors: Jack A. ELIAS, Chun Geun LEE, Bing MA, Suchitra KAMLE, Changmin LEE
  • Methods and compositions relating to anti-CHI3L1 antibody reagents for the treatment of cancer
    Patent number: 11667725
    Abstract: Described herein are methods and compositions relating to anti-Chi3L1 antibodies, antibody reagents, and antigen-binding fragments thereof which display superior properties, e.g., high sensitivity, high specificity, high binding affinity, neutralization activity ex vivo and in vivo (e.g., blocks Chi3L1-induced MAPK and AKT signaling). Methods of treatment, e.g., of treating cancer, obesity, and/or asthma by administering the compounds described herein are also provided.
    Type: Grant
    Filed: July 27, 2020
    Date of Patent: June 6, 2023
    Assignee: Brown University
    Inventors: Jack A. Elias, Chun Geun Lee, Chuan Hua He, Bing Ma, Suchitra Kamle, Chang-Min Lee
  • Methods and compositions relating to bispecific anti-CHI3L1 antibody reagents for the treatment of cancer
    Patent number: 11667726
    Abstract: It is demonstrated herein that inhibitors of immune checkpoints and CHI3L1 are synergistic. Accordingly, described herein are methods and compositions relating to combinatorial therapies for cancer, e.g., comprising an inhibitor of CHI3L1; and an inhibitor of an immune checkpoint protein. In some embodiments, the CHI3L1 inhibitor can be an antibody or antibody reagent as described herein.
    Type: Grant
    Filed: July 30, 2020
    Date of Patent: June 6, 2023
    Assignee: Brown University
    Inventors: Jack A. Elias, Chun Geun Lee, Chuan Hua He, Bing Ma, Suchitra Kamle, Chang-Min Lee
  • BISPECIFIC ANTIBODIES AGAINST CHI3L1 AND CTLA4 WITH ENHANCED CYTOTOXIC EFFECTS ON TUMOR CELLS
    Publication number: 20230046834
    Abstract: Described herein are bispecific antibodies simultaneously targeting both CHI3L1 and the immune checkpoint molecule CTLA4. These antibodies manifest enhanced synergistic cytotoxic effects compared to the effects of individual CHI3L1 and CTLA4 antibodies, alone or in combination. Methods of treating tumors, including lung and brain tumors by administering the bispecific antibodies described herein are also provided.
    Type: Application
    Filed: November 19, 2020
    Publication date: February 16, 2023
    Inventors: Jack A. Elias, Chun Geun Lee, Suchitra Kamle
  • Methods for decreasing chord length
    Patent number: 11478530
    Abstract: The methods and assays described herein relate to the diagnosis, prognosis, and treatment of subjects with emphysema, COPD, and/or cigarette-induced lung damage. In some embodiments, the methods and assays relate to subjects with a decreased level of NLRX1 expression. In some embodiments, the methods and assays relate to the administration of an agonist of NLRX1 and/or an inhibitor of MAVS.
    Type: Grant
    Filed: August 9, 2018
    Date of Patent: October 25, 2022
    Assignees: BROWN UNIVERSITY, YALE UNIVERSITY
    Inventors: Jack A. Elias, Chun Geun Lee, Min-Jong Kang
  • BISPECIFIC ANTIBODIES AGAINST CHI3L1 AND PD1 WITH ENHANCED T CELL-MEDIATED CYTOTOXIC EFFECTS ON TUMOR CELLS
    Publication number: 20220213193
    Abstract: Described herein are bispecific antibodies simultaneously targeting both CHI3L1 and the immune checkpoint molecule PD-1. These antibodies manifest enhanced synergistic cytotoxic effects compared to the effects of individual CHI3L1 and PD-1 antibodies, alone or in combination. Methods of treating a cancer by administering the bispecific antibodies described herein are also provided.
    Type: Application
    Filed: May 6, 2020
    Publication date: July 7, 2022
    Inventors: Jack A. ELIAS, Chun Geun LEE, Suchitra KAMLE
  • METHODS AND COMPOSITIONS RELATING TO THE TREATMENT OF FIBROSIS
    Publication number: 20220117987
    Abstract: Described herein are methods of treating fibrosis and fibrotic diseases with certain aminoglycosides, e.g., kasugamycin derivatives thereof.
    Type: Application
    Filed: January 7, 2022
    Publication date: April 21, 2022
    Inventors: Jack A. ELIAS, Chun Geun LEE, Chang-Min LEE
  • Methods and compositions relating to the treatment of fibrosis
    Patent number: 11219630
    Abstract: Described herein are methods of treating fibrosis and fibrotic diseases with certain aminoglycosides, e.g., kasugamycin derivatives thereof.
    Type: Grant
    Filed: August 17, 2018
    Date of Patent: January 11, 2022
    Assignee: Brown University
    Inventors: Jack A. Elias, Chun Geun Lee, Chang-Min Lee
  • METHODS AND COMPOSITIONS RELATING TO ANTI-CHI3L1 ANTIBODY REAGENTS FOR THE TREATMENT OF FIBROSIS
    Publication number: 20210395377
    Abstract: Described herein are methods and compositions relating to anti-CHI3L1 antibodies, antibody reagents, and antigen-binding fragments thereof which display superior properties, e.g., high sensitivity, high specificity, high binding affinity, neutralization activity ex vivo and in vivo (e.g., blocks CHI3L1-induced MARK and AKT signaling) Methods of treatment, e.g., of treating fibrosis by administering the compounds described herein are also provided.
    Type: Application
    Filed: November 7, 2019
    Publication date: December 23, 2021
    Inventors: Jack A. ELIAS, Yang ZHOU, Suchitra KAMLE, Chun Geun LEE
  • METHODS AND COMPOSITIONS RELATING TO THE TREATMENT OF FIBROSIS
    Publication number: 20210128595
    Abstract: Described herein are methods of treating fibrosis and fibrotic diseases with certain aminoglycosides, e.g., kasugamycin derivatives thereof.
    Type: Application
    Filed: August 17, 2018
    Publication date: May 6, 2021
    Inventors: Jack A. ELIAS, Chun Geun LEE, Chang-Min LEE
  • METHODS AND COMPOSITIONS RELATING TO ANTI-CHI3L1 ANTIBODY REAGENTS
    Publication number: 20210009712
    Abstract: It is demonstrated herein that inhibitors of immune checkpoints and CHI3L1 are synergistic. Accordingly, described herein are methods and compositions relating to combinatorial therapies for cancer, e.g., comprising an inhibitor of CHI3L1; and an inhibitor of an immune checkpoint protein. In some embodiments, the CHI3L1 inhibitor can be an antibody or antibody reagent as described herein.
    Type: Application
    Filed: July 30, 2020
    Publication date: January 14, 2021
    Inventors: Jack A. ELIAS, Chun Geun LEE, Chuan Hua HE, Bing MA, Suchitra KAMLE, Chang-Min LEE
  • METHODS AND COMPOSITIONS RELATING TO ANTI-CHI3L1 ANTIBODY REAGENTS
    Publication number: 20200354474
    Abstract: Described herein are methods and compositions relating to anti-Chi3L1 antibodies, antibody reagents, and antigen-binding fragments thereof which display superior properties, e.g., high sensitivity, high specificity, high binding affinity, neutralization activity ex vivo and in vivo (e.g., blocks Chi3L1-induced MAPK and AKT signaling). Methods of treatment, e.g., of treating cancer, obesity, and/or asthma by administering the compounds described herein are also provided.
    Type: Application
    Filed: July 27, 2020
    Publication date: November 12, 2020
    Inventors: Jack A. ELIAS, Chun Geun LEE, Chuan Hua HE, Bing MA, Suchitra KAMLE, Chang-Min LEE
  • Methods and compositions relating to anti-CHI3L1 antibody reagents to treat cancer
    Patent number: 10766968
    Abstract: It is demonstrated herein that inhibitors of immune checkpoints and CHI3L1 are synergistic. Accordingly, described herein are methods and compositions relating to combinatorial therapies for cancer, e.g., comprising an inhibitor of CHI3L1; and an inhibitor of an immune checkpoint protein. In some embodiments, the CHI3L1 inhibitor can be an antibody or antibody reagent as described herein.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: September 8, 2020
    Assignee: BROWN UNIVERSITY
    Inventors: Jack A. Elias, Chun Geun Lee, Chuan Hua He, Bing Ma, Suchitra Kamle, Chang-Min Lee
  • Methods and compositions relating to anti-CHI3L1 antibody reagents to treat nonalcoholic steatohepatitis (NASH), nonalcoholic fatty liver disease (NFALD) or metabolic syndrome
    Patent number: 10752700
    Abstract: Described herein are methods and compositions relating to anti-Chi3L1 antibodies, antibody reagents, and antigen-binding fragments thereof which display superior properties, e.g., high sensitivity, high specificity, high binding affinity, neutralization activity ex vivo and in vivo (e.g., blocks Chi3L1-induced MAPK and AKT signaling). Methods of treatment, e.g., of treating cancer, obesity, and/or asthma by administering the compounds described herein are also provided.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: August 25, 2020
    Assignee: Brown University
    Inventors: Jack A. Elias, Chun Geun Lee, Chuan Hua He, Bing Ma, Suchitra Kamle, Chang-Min Lee
  • METHODS AND COMPOSITIONS RELATING TO ANTI-CHI3L1 ANTIBODY REAGENTS
    Publication number: 20190119405
    Abstract: Described herein are methods and compositions relating to anti-Chi3L1 antibodies, antibody reagents, and antigen-binding fragments thereof which display superior properties, e.g., high sensitivity, high specificity, high binding affinity, neutralization activity ex vivo and in vivo (e.g., blocks Chi3L1-induced MAPK and AKT signaling). Methods of treatment, e.g., of treating cancer, obesity, and/or asthma by administering the compounds described herein are also provided.
    Type: Application
    Filed: December 21, 2018
    Publication date: April 25, 2019
    Applicant: BROWN UNIVERSITY
    Inventors: Jack A. Elias, Chun Geun Lee, Chuan Hua He, Bing Ma, Suchitra Kamle, Chang-Min Lee
  • Methods and compositions relating to anti-Chi3l1 antibody reagents
    Patent number: 10253111
    Abstract: Described herein are methods and compositions relating to anti-Chi3L1 antibodies, antibody reagents, and antigen-binding fragments thereof which display superior properties, e.g., high sensitivity, high specificity, high binding affinity, neutralization activity ex vivo and in vivo (e.g., blocks Chi3L1-induced MAPK and AKT signaling). Methods of treatment, e.g., of treating cancer, obesity, and/or asthma by administering the compounds described herein are also provided.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: April 9, 2019
    Assignee: Brown University
    Inventors: Jack A. Elias, Chun Geun Lee, Chuan Hua He, Bing Ma, Suchitra Kamle, Chang-Min Lee